Trials / Recruiting
RecruitingNCT07144462
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NEUK203-215 Injection in Adult Chinese Patients With Relapsed/Refractory Autoimmune Diseases
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 8 (estimated)
- Sponsor
- Neukio Biotherapeutics (Shanghai) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, tolerability and preliminary efficacy of NEUK203-215 , a healthy donor (HD) allogeneic CD19/BCMA-targeted CAR-NK cell product, in participants with severe, refractory autoimmune diseases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fludarabine | Specified dose on specified days |
| DRUG | Cyclophosphamide (C) | Specified dose on specified days |
| GENETIC | NEUK203-215 Injection | Specified dose on specified days |
Timeline
- Start date
- 2025-09-04
- Primary completion
- 2027-01-14
- Completion
- 2027-01-14
- First posted
- 2025-08-27
- Last updated
- 2025-08-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07144462. Inclusion in this directory is not an endorsement.